Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone. The discussion covered the clinical significance of achieving minimal residual disease (MRD) negativity, with Zandra correlating the depth of … Continue reading Phase 3 IsKia trial of Isatuximab+ KRd in Multiple Myeloma [ASH 2023]